More specifically, PPARα regulates lipid metabolism by targeting fatty acid and acyl-CoA and thus acts as protective factor in dyslipidemia, whereas PPARγ increases tissue insulin sensitivity and is a pharmaceutical target in diabetes mellitus. This evidence concerns the gene PPARG and metabolic syndrome.